Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05168813Phase 2Completed

Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern

Role: lead

NCT06585683Completed

Post-Trial Tuberculosis Case Finding: A Substudy of CoVPN 3008

Role: lead

NCT04431414Completed

A Study of Immune Responses to the Virus That Causes COVID-19

Role: lead

NCT04658121Completed

SARS-CoV-2/COVID-19 Prevalence Study

Role: lead

All 4 trials loaded